大细胞脂酶D3通过加剧泡细胞的形成和诱导炎症反应促进动脉样硬化
Teng Li1, Xiaobao Gu1, Xiangyang Yin1
1Department of Vascular Surgery, The Fifth Affiliated Hospital of Zhengzhou University, Zhengzhou, China.
International journal of cardiology. Heart & vasculature
|November 17, 2025
概括
脂酶D3 (PLD3) 通过增加巨细胞中的脂质积累和炎症来促进动脉样硬化. 准PLD3可能是治疗这种心血管疾病的新治疗策略.
科学领域:
- 心血管生物学 心血管生物学
- 免疫学 免疫学 免疫学
- 分子医学是分子医学.
背景情况:
- 动脉样硬化是一个重大的全球健康负担.
- 脂酶D3 (PLD3) 在动脉样硬化斑块中发现,但其功能尚不清楚.
- 了解PLD3的作用对于开发新疗法至关重要.
研究的目的:
- 研究PLD3在动脉样硬化中的作用和分子机制.
- 为了确定PLD3是否是一个可行的治疗目标.
主要方法:
- 人类动脉样硬化组织的单细胞RNA测序.
- 使用THP-1巨细胞和ApoE^-/-小鼠进行了体外研究.
- 降低PLD3,氧化LDL刺激,脂质积累分析和细胞因子量化.
- RNA测序以分析下游途径.
主要成果:
- 在动脉样硬化病变和巨细胞中,PLD3被上调,显示出诊断潜力.
- 氧化的LDL会增加巨细胞中的PLD3表达.
- 通过降低CD36的调节,PLD3沉默降低了脂质积累,并降低了炎症性细胞因子 (IL-1β,TNF-α).
- 缺少PLD3会抑制NF-κB通路的发生.
结论:
- 通过增强CD36介导的脂质吸收和NF-κB驱动的炎症,PLD3促进动脉样硬化.
- PLD3是动脉样硬化疾病的潜在治疗标.
相关概念视频
Inflammation
61.5K
Overview
61.5K
Atherosclerosis I: Introduction
853
Atherosclerosis is a progressive disorder characterized by the buildup of plaques on the arterial inner wall, causing them to narrow and harden over time. These plaques comprise lipids, calcium, blood components, carbohydrates, and fibrous tissue. The process primarily affects the intima of large and medium-sized arteries, reducing blood flow in any artery.Etiology and risk factorsThe cause of atherosclerosis is multifactorial, involving a complex interplay among endothelial injury, lipid...
853
Coronary Artery Disease II: Pathophysiology
355
Coronary Artery Disease (CAD) originates from a series of events that impair the function of coronary arteries, the blood vessels responsible for delivering oxygen-rich blood to the heart muscle. The pathophysiology of CAD is closely linked to atherosclerosis, a chronic inflammatory and lipid-driven condition affecting the vascular endothelium.1. Endothelial DamageThe process begins with damage to the vascular endothelium, which serves as a protective barrier between the blood and the vessel...
355
Peripheral Artery Disease I: Introduction
295
Peripheral artery disease (PAD) predominantly results from atherosclerosis, which involves the accumulation of fatty deposits, or plaques, within the walls of arteries. This causes them to narrow and harden, significantly reducing blood flow. PAD predominantly affects the legs, particularly the arteries supplying the thighs and calves. In rare cases, it may involve other arteries, including those in the arms.Etiology of PAD:The principal cause of PAD is atherosclerosis, which results from fatty...
295
Atherosclerosis III: Management
307
Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
307
IP3/DAG Signaling Pathway
14.2K
Membrane lipids such as phosphatidylinositol (PI) are precursors for several membrane-bound and soluble second messengers. Specific kinases phosphorylate PI and produce phosphorylated inositol phospholipids. One such inositol phospholipids are the phosphatidylinositol-4,5 bisphosphate [PI(4,5)P2], present in the inner half of the lipid bilayer. Upon ligand binding, GPCR stimulates Gq proteins to turn on phospholipase Cꞵ. Activated phospholipase Cꞵ cleaves PI(4,5)P2 and...
14.2K


